Yao-bin Liu

发表

A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade

Miguel Ángel Martínez, A. Mondal, T. Logtenberg, 2021, Nature Communications.

A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade

Miguel Ángel Martínez, A. Mondal, T. Logtenberg, 2021, Nature communications.

A Novel CRAd in Combination With Cisplatin Enhanced the Antitumor Efficacy in Ovarian Cancer

Junnian Zheng, Xiaoxin Yin, Peiying Zhang, 2011, International Journal of Gynecologic Cancer.

PD-L1 Inhibits T Cell-Induced Cytokines and Hyaluronan Expression via the CD40-CD40L Pathway in Orbital Fibroblasts From Patients With Thyroid Associated Ophthalmopathy

Feila Liu, Hongfeng Yuan, Zhibin Liu, 2022, Frontiers in Immunology.

820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells

P. Loo, A. Mondal, T. Logtenberg, 2020, Journal for ImmunoTherapy of Cancer.

Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma

Yao Liu, Jiabin Wang, Lianjun Liu, 2020 .

mir-182 promotes tumor growth and increases chemoresistance of human anaplastic thyroid cancer by targeting tripartite motif 8

Bing Zhang, H. Qin, T. Shi, 2017 .

A Novel CRAd in Combination With Cisplatin Enhanced the Antitumor Efficacy in Ovarian Cancer

Junnian Zheng, Xiaoxin Yin, Peiying Zhang, 2011, International Journal of Gynecologic Cancer.

Biomarker Profiles in Trastuzumab (T) Refractory HER2+ Inflammatory Breast Cancer (IBC) That Predict for Survival Benefit from Lapatinib (L) Monotherapy.

C. Swanton, S. Stein, S. Johnston, 2009 .